Evidence map›Paper›PMID 41760631›Full record

ReviewNPJ microgravity2026

Orbital biomanufacturing: the key to space resiliency, operational persistence, and ethical sustainability.

Andrew Kd Younger

Abstract readReview
In one paragraph

Review in NPJ microgravity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Andrew Kd YoungerBlue Jay Advising LLC, Alexandria, VA, USA. andrew@bluejayadvising.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Space-based biomanufacturing has historically focused on long-duration crewed and exploration missions, but its greater potential lies in supporting in-space logistics, manufacturing, and servicing in Earth orbit. This article provides a strategic perspective on how shifting investments, policy, and R&D to orbital biomanufacturing could revolutionize defense, commercial, and civil sectors by enhancing supply chain resiliency, operational flexibility, ethical debris management, and commercial viability in Earth orbit.

Identifiers

PMID41760631
PMCPMC13066452

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.